|Copyright 2006-2010 Abiant, Inc.
|Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030
DEERFIELD, ILLINOIS, September 9, 2008. Abiant, Inc. announced today that a poster co-authored
together with scientists from Johnson & Johnson and GlaxoSmithKline was presented at the 2008
World Molecular Imaging Conference in Nice, France. The poster, titled "Standardization of 11C-
raclopride PET Imaging Protocols for Clinical Trials for the Pharmaceutical Industry", focused on the
impact of data analysis methodologies upon imaging study results.
The poster describes factors that can impact consistency of results regarding the degree to which a
drug binds to particular receptors in the brain such as dopamine. Studies of receptor binding can be
highly useful in determining whether a drug binds to its intended chemical target in the living brain.
Abiant has focused upon the high quality standardization of image data processing approaches in
order to provide pharmaceutical customers with reliable data for drug development decision making.
A copy of the poster is available by clicking on the following link: WMIC Poster.
Abiant, Inc. uses proprietary image analysis methods and software to provide a sensitive biomarker
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, can be used to accelerate or reduce risk of decision
making in both drug development and disease treatment. The Company’s focus areas include the
central nervous system, oncology, and inflammation. Further information can be found at www.
Forward Looking Statements
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
Abiant, Inc. Co-Authors Poster Presented at World Molecular Imaging Conference